Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.

The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Latest Announcements


23/02/2017
Appendix 4D and Half Year Financial Report
25/01/2017
December 2016 Appendix 4C – Quarterly
11/01/2017
Investor Presentation January 2017
11/01/2017
PTX to present at Biotech Showcase 2017 in San Francisco
16/12/2016
Change of Registry Address
14/12/2016
First Patient Dosed on Phase 1b/2 AML Trial